Achalasia cardia (AC) is a frequently encountered motility disorder of the esophagus resulting from an irreversible degeneration of neurons. Treatment modalities are palliative in nature, and there is no curative treatment available for AC as of now. Significant advancements have been made in the management of AC over last decade. The introduction of high resolution manometry and per-oral endoscopic myotomy (POEM) has strengthened the diagnostic and therapeutic armamentarium of AC. High resolution manometry allows for the characterization of the type of achalasia, which in turn has important therapeutic implications. The endoscopic management of AC has been reinforced with the introduction of POEM that has been found to be highly effective and safe in palliating the symptoms in short-term to mid-term follow-up studies. POEM is less invasive than Heller's myotomy and provides the endoscopist with the opportunity of adjusting the length and orientation of esophageal myotomy according to the type of AC. The management of achalasia needs to be tailored for each patient, and the role of pneumatic balloon dilatation, POEM, or Heller's myotomy needs to be revisited. In this review, we discuss the important aspects of diagnosis as well as management of AC. The statements presented in the manuscript reflect the cumulative efforts of an expert consensus group.
Introduction
Achalasia cardia (AC) is a primary motor disorder of the esophagus characterized by insufficient lower esophageal sphincter (LES) relaxation and loss of esophageal peristalsis. The latest guideline on the diagnosis and management of AC was published in 2013 by the American College of Gastroenterology. 1 There is a paradigm shift in management of AC after introduction of high resolution manometry (HRM) and per-oral endoscopic myotomy (POEM). Although data are still emerging, we have many studies describing efficacy of POEM and its comparison to conventional modalities.
The working group meeting was organized in 2016 in Hyderabad, India, and the group felt that the guidelines on the diagnosis and treatment of AC needs to be revised according to the recent advancements. Therefore, the goal of this consensus was to establish recommendations and managements of AC with specific relevance to standard approach and recent advances in therapy.
Methods
A modified Delphi process was performed to establish the consensus. 2 This process is based on evidence-based medicine and an anonymous voting system. The opinions of the consensus panel were supported by a systematic literature review. List of statements prepared by panel of physicians was distributed electronically to all the members in advance. The statements were divided into two broad sections, namely, the diagnosis and treatment of AC. Consensus group were invited for discussion, revision, and voting on these statements. Literature review team assembled the literature and uploaded the articles to password secured website. Systematic literature reviews, with defined inclusion and exclusion criteria, were conducted to identify and grade the available evidence to support each statement. Literature search was conducted in English language using MEDLINE, EMBASE, and the Cochrane Trials Register in human subjects. Categorization of evidence, classification of recommendation, and voting schema was modified from the Canadian Task Force on the periodic health examination. 3 The first vote was conducted electronically by email, without explanation or access to the relevant literature. The second vote was conducted electronically after web-based access to the provided literature. All feedbacks were collated before the face-to-face meeting. Face-to-face meeting of the consensus group was held in Hyderabad, India, to review and discuss the evidence for all statements. Final edition was done after agreement of the participants during plenary session. Statements with overlapping data were rewritten before the last voting. Consensus was achieved when 80% or above of voting members indicated "accept completely" or "accept with some reservation." A statement was refuted when 80% or above of voting members "reject completely" or "reject with some reservation." Grading was done for every accepted statement, and each statement was given the level of evidence and the strength of recommendation. Modification was done for those statements in which consensus was not achieved. After discussion, appropriate corrections were done based on the reasons for rejection and then further re-voting was done. Even after modification if a statement still failed to reach consensus, that statement was dropped from the list. Commentaries on statements were written by the chairmen and the persons assigned to present the statements during the face-to-face meeting. Coauthors were involved in the final editing of the commentaries, and consensus on manuscript was achieved after discussions and careful review of the literature Statement 1a. The management of Achalasia Cardia should be individualized based on findings of highresolution manometry and patient demographics.
Quality of evidence: 2+ Classification of recommendation: B Statement 1b. Graded pneumatic balloon dilation and laparoscopic Heller's myotomy with partial fundoplication are equally effective as first line treatment options for patients with type I and type II Achalasia Cardia.
Quality of evidence: 2+ Classification of recommendation: B
The Chicago classification for categorizing esophageal motility disorders by HRM was first released in 2009 and has undergone multiple revisions since then. 4 HRM uses sensors placed throughout the esophagus to estimate pressure at multiple points during swallowing. The Chicago classification uses a hierarchical approach and categorizes AC into three manometric subtypes based upon the HRM findings. Type I AC, also called classic achalasia, is characterized by absent esophageal body smooth muscle contractility and lack of compartmental pressurization of the esophagus. These findings may represent late stage achalasia in which there is loss of muscle tone and subsequent dilation of the esophageal body. Type II AC, the most common type, is characterized by periods of compartmentalized esophageal pressurization or esophageal compression; the smooth muscle of the esophagus retains its tone and there are pan-esophageal isobaric pressure increases seen on swallow, in addition to increases in intrabolus pressure secondary to esophageal longitudinal muscle contraction. If 20% or more of the patient's swallows exhibit this panesophageal compartmentalized pressurization, the achalasia is classified as type II. Type III achalasia, the least common type of achalasia, is characterized by spastic contraction of the distal esophagus, seen in at least 20% of swallows. 5, 6 There is evidence to indicate that it may be important to treat achalasia based on manometric subtype. A meta-analysis from 2016 included nine studies with 297 cases of pneumatic dilation (PD) and 429 cases laparoscopic Heller's myotomy (LHM). [5] [6] [7] [8] [9] [10] [11] Important to note is that each of these studies included only a small sample of patients, especially those with type III achalasia, and the follow-up periods were highly variable, ranging from a mean of 6 to 34 months. [5] [6] [7] [8] [9] [10] [11] Seven of these studies compared treatment response in those patients with types I and II achalasia. [5] [6] [7] [8] [9] [10] [11] Overall, patients with type II achalasia responded better to treatment than those patients with type I achalasia, both when treated with PD ( 5-11 Seven studies also compared treatment response in patients with types I and III achalasia. [5] [6] [7] [8] [9] [10] [11] From meta-analysis, it was concluded that overall, type I patients responded better to treatment than type III patients. In a study by Rohof et al., the relationship between treatment response and manometric subtypes of achalasia was evaluated in 176 subjects. In this study, the subtypes of achalasia included 44 (25%) type I, 114 (65%) type II, and 18 (10%) type III achalasia. 6 After a minimum of 2-year follow-up, treatment success was 81%, 96%, and 66% in types I, II, and III patients, respectively. Furthermore, in type II patients, the success rate after PD was 100% versus a 93% after LHM. At 5 years, the treatment success of LHM versus PD was 75% versus 69% in type I, 88% versus 96% in type II, and 86% versus 48% in type III AC.
Other factors that may affect treatment response are age/gender and presence of chest pain. Moonen et al. reported that patients 40 years or older were more likely to respond to treatment than patients younger than 40 years. 12 However, there were similar rates of response between male and female patients, and among patients with or without chest pain.
Achalasia subtyping is useful in the clinical setting because it may predict the likelihood of the patient's response to treatment and allow the clinician to choose the best treatment option for the patient based upon HRM findings. For those patients with type II achalasia, similar treatment response is seen in both PD and LHM. Limitations of the published studies include retrospective design, lack of randomization stratified according to achalasia subtypes, and small number of patients with type III achalasia.
Statement 2. POEM is a minimally invasive method of myotomy and has equal efficacy and safety as compared with LHM with partial fundoplication.
Quality of evidence: 2++ Classification of recommendation: B
Per-oral endoscopic myotomy was introduced by Inoue et al. as an endoscopic alternative to Heller's myotomy. 13 Since then, numerous studies have been published demonstrating the safety and efficacy of POEM for AC in short-term. [14] [15] [16] [17] [18] The literature regarding long-term efficacy of POEM is limited. Few studies with relatively long follow up (≥2 years) conclude that POEM is effective in >90% patients with AC.
The studies comparing POEM with the current gold standard of myotomy, that is, LHM, have concluded that both the modalities are equally effective and safe. [20] [21] [22] [23] [24] [25] [26] [27] Besides equal efficacy, POEM was found to be associated with less blood loss, 21, 22 shorter operative time, [20] [21] [22] 27 less postoperative pain and analgesic use, 21, 22, 28 shorter hospital stay, 20, 26 and quicker return to normal activities. Two studies compared the cost-effectiveness of POEM with LHM 29 and robotic LHM, 30 respectively. The cost of POEM was found to be equivalent to LHM but less than robotic LHM. 29, 30 The literature on frequency of development of gastroesophageal reflux disease (GERD) diagnosed using objective modalities following POEM as compared with the other treatment modalities is scanty. 20, 26, 27 In POEM, limited hiatal dissection is performed in contrast to LHM thereby theoretically reducing the chances of GERD. On the other hand, there is no anti-reflux procedure accomplished in POEM as opposed to LHM where partial fundoplication is usually performed. In a comparative study, Bhayani et al. concluded that postoperative abnormal esophageal acid exposure was similar in both the groups (POEM-39%, LHM-32%; p-0.7). 20 Another study found equivalent GERDrelated quality of life outcomes after both LHM and POEM. 21 In contrast, the incidence of GERD (endoscopy and pH-analysis) was higher after POEM as compared with LHM with fundoplication. 27 Esophagitis at endoscopy was found in 40% and 5% patients in POEM and LHM groups, respectively. Whereas, high DeMeester score was detected in 28% and 22% patients in both groups, respectively. 27 A recent meta-analysis concluded that POEM was more likely to be associated with GERD quantified by symptoms, erosive esophagitis, and pH-analysis. 31 Several published systemic reviews and meta-analyses suggest that POEM has equal or higher efficacy as compared with LHM at least in short-term. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] However, all the published metaanalyses are limited by absence of long-term follow up and lack of prospective randomized controlled studies. As the first procedure was performed less than a decade ago, long term follow-up studies of POEM are not available. Therefore, long term followup studies and randomized comparison with LHM are required before concluding the equivalence of these two treatment modalities. The subtyping of achalasia with HRM (Table 1) has important implications on subsequent response to treatment. 9 Type III AC appears to be distinct from type I/II AC, as in the former subtype, distal esophageal smooth muscle is hyperactive in addition to gastroesophageal junction (GEJ). 46 Per-oral endoscopic myotomy is a recent addition to the endoscopic armamentarium for AC. Endoscopic myotomy may be especially useful in patients with spastic achalasia, where a long myotomy is often required, which may not possible via a laparoscopic transhiatal approach. Limited data suggest that POEM may be effective across the spectrum of AC. 18, 47 There is only one study comparing the outcomes of LHM and POEM for type III AC. In this study, clinical success was significantly higher in the POEM group as compared with LHM group (98.0% vs 80.8%; P = 0.01). The incidence of adverse events was significantly lower in the POEM group (6% vs 27%; P = 0.001). The authors attribute higher clinical success to the longer length of myotomy in the POEM group (16 cm vs 8 cm; P < 0.01). 48 In another study, 96% of patients with type III AC responded to POEM. The mean length of myotomy in this study was 16.4 cm (range 7-26 cm). 45 Similar conclusion was drawn in a study where the response of type III AC to POEM was 87.5% at 1 year and was not significantly different from that of types I (91.3%) and II AC (96.3%). 18 A recent systematic review and meta-analysis analyzed the efficacy of POEM for spastic esophageal disorders. This review included results from eight observational studies and consisted of a total of 179 patients of which 116 had type III AC. The clinical success in this subgroup (type III AC) was 92%, and the weighted pool rate of adverse events (AEs) was 11% (6, 19%). 43 There is no randomized comparison between LHM and POEM for type III AC. As of now, LHM is considered the optimal treatment option for this subgroup of AC, despite a high rate of clinical failure. POEM has the potential to improve the outcomes of this subgroup due to its ability to extend esophageal myotomy according to HRM findings.
Statement 4a. Botox injection should be reserved for elderly patients and those with comorbidities who are not fit for PD, LHM, and POEM. 
Quality of evidence: 1+ Classification of recommendation: A
The mainstay of management of AC includes graded pneumatic balloon dilatation (PD) and myotomy (surgical or endoscopic). However, the surgical risk associated with PD and myotomy may not be appropriate for elderly patients or patients with complex comorbidities. 42, 44 Therefore, injection of botulinum toxin (BT) into the LES may be a treatment option for non-surgical candidates. Additionally, treatment with BT might also be beneficial where other treatment modalities have failed.
Botulinum toxin inhibits the exocytosis of excitatory acetylcholine from the presynaptic neurons, restores the balance between excitatory and inhibitory influences, and allows muscular relaxation and subsequent decrease in LES pressure. 49 Use of BT in AC treatment was first described by Pasricha et al. in 1994 via a prospective trial of 10 symptomatic adult achalasia patients. 49 An 80 U of BT was injected through a sclerotherapy needle into the LES (1 mL of a 20 U/mL solution into each of the four quadrants). One week post-treatment, clinical scores (measuring dysphagia, regurgitation, and chest pain) decreased from 5.3 ± 0.4 to 0.7 ± 0.3.
In 1995, Pasricha et al. reported a second double-blind trial involving 21 symptomatic AC patients who received either 80 U of BT injected into the LES or placebo; results were assessed 1 week after the treatment. The study showed local injection of botulinum toxin was safe and effective in patients with AC. There were no serious AEs reported in this study. 50 Several studies showed clinical response following BT injection at 1 month remained 75% to 93%; at 6 and 12 months, the response rate ranged from 37% to 68% and from 29% to 67%, respectively, showing a clear decreased efficacy of BT over time. [51] [52] [53] [54] [55] The literature is inconsistent with regard to dose of BT injection (25-100 U), techniques, and scheduling. A prospective randomized trial of 118 achalasia patients receiving one of three doses (50, 100, 200 units) and one of two schedules (one injection or reinjection in 30 days) of botox injections showed better response to 100 units injection given at 30 days apart compared with others. 56 The clinical effect of BT injection may also be compared with effect seen with other treatment modalities. Various studies and meta-analysis showed that pneumatic dilatation or myotomy is superior to BT in treatment of achalasia. 42, 57 Injection of BT may also be important in patients with a history of failed PD or myotomy, or it may be used as a "bridge" treatment for symptomatic relief before a more invasive procedure. 58 Repeated BT injections may lead to subsequent submucosal fibrosis making future therapy (pneumatic dilatation or myotomy) difficult. 59, 60 Post injection side-effects were infrequent, including transient chest pain, heartburn, and epigastric pain. 44 No ulceration, perforation, pneumothorax, or abscess were reported. Deaths is reported from acute mediastinitis following BT injection into body. 61, 62 Injection with BT is a safe treatment option for those elderly patients or patients with complex comorbidities deemed unfit for more invasive therapy. 44 Older patients and those with vigorous achalasia (type III achalasia in the Chicago classification) were most likely to respond to endoscopic BT injection (EBTI). 56, 62 Statement 4b. Oral pharmacological therapy is not effective in long term management of AC.
Quality of evidence: 2+ Classification of recommendation: A Oral pharmacological therapy is least popular treatment for AC because of its low efficacy. Drugs have a transient effect on LES and induce suboptimal change in LES pressure. Current oral drugs used to treat AC include nitrates, calcium channel blockers, phosphodiesterase inhibitors, and some others (butylscopolamine, nifedipine, verapamil, carbutoerol, terbutaline, aminophylline, nitroglycerin, vasoactiveintestinalpeptide, cimetropium, loperamide, isosorbide, and sildenafil). [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] These drugs transiently relax LES smooth muscle and facilitate esophageal emptying.
Studies on use of these pharmacological therapies are on small numbers of patients and are uncontrolled. Very few placebo controlled studies (single-blind or double-blind) are available. 67, [76] [77] [78] [79] The percentage of LES pressure reduction was reported among 30-70% patients. Efficacy of medication ranged from 14% to 79% over period of 3-21 months. [76] [77] [78] [79] [80] [81] [82] [83] Changes in LES pressure was not constant among various studies. A few studies showed that there was no change in LES pressure with medication. 79 The most commonly employed calcium channel blocker is nifedipine. Its effect is highest 20-45 min after ingestion and lasts from 30 to 120 min. For best response, nifedepine (10-30 mg) should be ingested sublingually 30-45 min before meals. Improvement in symptoms varies from 0% to75% and 30% of patients may experience side effects.
Compared with calcium channel blockers, sublingual isosorbide dinitrate not only reduces LES pressure effectively (30-65%) but also improves symptoms by 53-87%. Duration of effect for nitrate is shorter (30-90 min), and peak effect usually occurs 3-27 min after ingestion. So isosorbide dinitrate (5 mg) should be administered sublingually 10-15 min before meals. The only comparative study of sublingual nifedipine to sublingual isosorbide dinitrate showed that both the drugs reduced LES pressure and pressure wave amplitude, but the effect of isosorbide dinitrate was faster and more intense than that of nifedipine. Although statistically not significant, LES pressure reduction with the isosorbide dinitrate (65%) was slightly higher compared with nifedepine (49%). 73 However, nitrates are not popular because of high frequency of side-effects.
Advantage of medical therapy is its low cost and associated low complication rates. Drawback of the pharmacological therapy is tachyphylaxis. Efficacy of medication decreases substantially over a period. Side-effects increases with increase in dose of medication and it includes peripheral edema, headache, and hypotension. 84 The research to date shows drugs such as nitrates and calcium channel blockers are not useful as primary treatment due to poor efficacy, side-effects, and development of tachyphylaxis. However, drugs can be used as a temporary measures as bridge to therapy (when patients are awaiting for surgery or endoscopic therapy) or, "on demand" for severe chest pain. These drugs can also be used to occasionally treat spasms and chest pain after the interventional treatment of achalasia. Quality of evidence: 2+ Classification of recommendation: C AC is a chronic disease and treatment failure defined as persistence or recurrence of symptoms is not uncommon during longterm follow up. Relapse of symptoms and need for re-treatment are more frequent with PD as compared with LHM. The long-term results of European achalasia trial revealed that 25% of patients in PD group required re-dilation during follow up. 12 The predictive factors for relapse of symptoms after PD include young age, residual LES pressure > 10 mmHg, stasis on timed barium esophagogram (TBE), and male sex. [85] [86] [87] [88] In addition, patients with type III AC do not respond well to PD. 6, 10 The causes for treatment failure post-LHM include incomplete myotomy, fusion, or fibrosis of the myotomy line, failure of anti-reflux procedure, and gastroesophageal reflux. 89 The treatment options for treatment failure include PD and LHM for patients who underwent LHM and PD as their initial treatment, respectively. The short-term response to PD after LHM failure was adequate in one study. However, long-term relapse was frequent and re-dilations were required. 90 Re-myotomy (surgical) is an option in these patients, although the extent of improvement in symptoms is less as compared with initial myotomy. Moreover, redo surgical myotomy is invasive and conversion to open procedure may be higher. 91 Per-oral endoscopic myotomy has emerged as a less invasive treatment options for naïve as well as for prior treatment failure patients. The published literature suggests that POEM is a safe and efficacious alternative to LHM or PD for treatment of failed cases of AC.
18,92-104 Vigneswarwan et al. concluded that POEM is feasible in failed cases of LHM, and fundoplication does not hinder successful outcomes. 92 In a recent multicenter study, the outcome of POEM was evaluated in 90 patients who underwent prior Heller's myotomy. POEM was successfully accomplished in 98% of patients. Although the clinical response was less frequent in LHM group as compared with non-LHM group (81% vs 94%), there was no difference in the rate of AEs. 94 In another study including 51 patients with prior Heller's myotomy, POEM was successfully performed in all the cases. The long-term clinical success was achieved in 94% of patients. 99 In summary, POEM appears to be safe alternative to LHM or PD for treatment of failed cases of AC. Randomized and long-term follow up studies are required to conclude on the role of POEM in treatment failure cases. Sigmoid esophagus is the end-stage in the progression of AC and accounts for 5% of cases. Progression of disease in absence of any treatment leads to massive dilatation of the esophagus with axis deviation and tortuosity resulting in a sigmoid or "tortuous" or "end-stage" esophagus. 105 Even after treatment, 10% of cases progresses to end-stage achalasia requiring esophagectomy. 106 Definition of sigmoid esophagus is not consistent in the literature. A sigmoid esophagus is tortuous (diameter > 6 cm) with axis deviation. 107, 108 Sigmoid achalasia further classified into two types on the basis of computed tomography (CT)-(i) Sigmoid type 1 (S1): the esophagus is significantly dilated and tortuous with single lumen only, (ii) Sigmoid type 2 (S2): the esophagus is very dilated and tortuous with double lumen on single CT slice. 13 End-stage achalasia can lead to recurrent aspiration, esophageal stasis leading to ulceration, bleeding, fistulization, or perfortion of the esophageal body, and development of cancer in some cases.
The management of end-stage achalasia is challenging. The decision regarding conventional treatment versus esophagectomy should be individualized. In end-stage achalasia, botox injections will likely provide minimal temporary palliation, and pneumatic dilatation is associated with increased risk of perforation. Results with laparoscopic myotomy or POEM are not consistent and may vary according to type of sigmoid. Still these measures should be considered when patient is not a candidate for radical surgery. For sigmoid esophagus, LHM and POEM showed good results.
14,107-110 Hu et al. and Lv et al. reported their experience of POEM in AC. 109, 110 The procedural difficulties encountered in these patients include difficult submucosal tunneling, longer duration, and difficulty in maintaining vertically downward direction. Posterior myotomy may be recommended as preferred approach because of the spine that may be used as landmark for orientation. Lv et al. 109 reported a series of 23 patients who underwent POEM for end-stage AC (19 with S1 type and 4 with S2 type achalasia). Clinical success achieved was 95%. Authors performed 7-10 cm of full thickness myotomy posteriorly. They also reported post procedural improvement in the morphology of the esophagus including curvature straightening and diameter reduction.
Despite symptom improvement offered to achalasia patients by either PD or surgical myotomy, 10% to 15% progresses to end-stage and up to 5% may eventually require an esophagectomy. 111, 112 Esophagectomy must be indicated for end-stage disease (tortuous or sigmoid esophagus) and persistent dysphagia after failed interventions. When performed by experienced hands, the procedure can be undertaken successfully, with acceptable postoperative morbidity and mortality. Esophagectomy with reconstruction (stomach or colon) results in improvement of symptoms, and a good long-term quality of life in the majority of patients.
Esophagectomy for end-stage achalasia can be performed through transhiatal, or transthoracic routes or by minimally invasive access. Problems with the transhiatal approach include difficulty in mobilizing the dilated esophagus, risk of perforation, opening of pleural cavity (axis deviation), and increased bleeding due to hypertrophic muscle. Problems with the transthoracic approach include morbidity of thoracotomy and risk of anastomotic leak in the chest. Lastly, the problems associated with minimally invasive approaches are need for a high level of skill and scarcity of adequately experienced surgeons. 113, 114 A retrospective study conducted by Devaney et al. looked at 20 years of patient data and during that time, 93 patients underwent esophagectomy for achalasia. 115 Indications for esophagectomy to treat AC include megaesophagus in 59 (64%) and 9 (10%) of those with no prior treatment, and prior esophageal procedure in 85 (90%) including dilatation in 66 (71%), myotomy in 58 (62%), anti-reflux operation in 29 (31%), and other in 16 (17%). Overall functional result was excellent in 26 (29%), good in 38 (42%), fair in 25 (27%), and poor in 2 (2%).
Definition of end-stage achalasia, however, should be standardized to achieve consistent results in different studies. Treatment of end-stage achalasia should be individualized considering morphology of esophagus, history of prior intervention, and associated comorbidities. Nowadays, there is a gradual shift towards less invasive therapy for the initial management of sigmoid achalasia. Esophagostomy still remains the only option for many patients with sigmoid esophagus or those in whom myotomy and other treatment modalities had failed. There is great need for large multicenter and randomized control studies to provide definitive data regarding various treatment options in the management of endstage achalasia. Objective methods used to evaluate clinical response in AC patients to treatment include TBE, esophageal manometry, and endolumenal functional lumen imaging probe. In addition, patient-reported symptoms can be objectively assessed by Eckardt score.
The vagal afferent response may be impaired in achalasia patients, resulting in higher threshold for symptoms and potential overestimation of the treatment success. 116 In a study by Vaezi et al., 116 nearly 30% (10/34) of patients with achalasia reported complete symptom relief following PD despite of poor esophageal emptying (<50%) on TBE. At 1-year follow up, 9/10 (90%) of these patients were treatment failures. In contrast, only 2/22 (9%) of patients with adequate emptying had treatment failure (P < 0.001). Therefore, patient-reported symptoms alone may not be reliable, and it is important to objectively measure the treatment success in these patients. 116 Timed barium esophagogram is an objective method of quantifying esophageal emptying. Esophageal emptying is dependent on its contractility and residual LES pressure on swallowing. The patient ingests 100-250 mL of a 45% barium sulfate suspension in 15-20 s, in order to allow for adequate filling of the esophagus. 117 Radiographs in the standing position are taken at 1, 2, and 5 min after the solution is ingested. 117 Height and width of the barium column can then be used to measure esophageal emptying as a function of time. 117 TBE may also be a valuable predictor for the need of retreatment after PD. 118 Measuring LES pressure on esophageal manometry is another objective method that can be used to predict treatment outcomes and recurrence rate in achalasia patients. In a retrospective study by Ghoshal et al., 87 failure to achieve at least 50% reduction in LES pressure from baseline was associated with a poor outcome after PD.
Similarly, a post-PD LES pressure of <10 mmHg has been found to be predictor of good long-term response in other studies as well. 85, 119 In a retrospective study, Rohof et al. 6 compared TBE and esophageal manometry at assessing the treatment response. Interestingly, there was a lack of correlation between LES pressure and clinical symptoms as well as barium retention. At 10-year follow up, 80% (12/15) of patients with good esophageal emptying initially, remained in remission while only 19% (5/26) with abnormal esophageal emptying were in remission at 10-year follow up. The overall results from this study indicate that esophageal stasis, rather than LES pressure, may be the most important indicator of long-term treatment success in patients with achalasia.
In another prospective study, TBE and esophageal manometry were found equivalent in assessing treatment response to PD. TBE and esophageal manometry showed concordance with clinical response in 44/62 (71%) and 42/62 (68%) of subjects at 6 months, respectively. 120 In conclusion, treatment success in patients with achalasia should be objectively determined. TBE and high-resolution manometry are equally useful in measuring treatment response.
Conclusion
A workgroup of experts established seven consensus statements regarding management of achalasia cardia. Overall, the consensus points to recent advancement in management of AC and includes management guided by HRM. POEM is recent addition to armamentarium in endoscopic management of achalasia cardia. In this consensus, data on POEM were critically reviewed, and separate statement are given on its current scenario. Other statements included the conventional methods of treatment of AC like drugs, botulinum toxin, laparoscopic Heller's myotomy with fundoplication, and role of surgery in management of end-stage achalasia cardia.
